Progesterone Receptor antibody (PR) content of breast cancer tissue is an important parameter in the prediction of prognosis and response to endocrine therapy. PR  is directed against the human progesterone receptor molecule. A prokaryotic recombinant protein, corresponding to the N-terminal region of the A-form of human progesterone receptor, was used as the immunogen. Antibody characterization studies demonstrated that PR  reacts with both A- and B- forms of human progesterone receptor in Western Blotting procedures.
There are no reviews yet.